首页> 外文期刊>Journal of Analytical Toxicology >Comparison and evaluation of DRI methamphetamine, DRI ecstasy, Abuscreen ONLINE amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetami
【24h】

Comparison and evaluation of DRI methamphetamine, DRI ecstasy, Abuscreen ONLINE amphetamine, and a modified Abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetami

机译:DRI甲基苯丙胺,DRI摇头丸,Abuscreen ONLINE苯丙胺和改良的Abuscreen ONLINE苯丙胺筛选免疫测定法的比较和评估,用于检测苯丙胺(AMP),甲基苯丙胺(MTH),3,4-亚甲基二氧苯丙胺

获取原文
获取原文并翻译 | 示例
       

摘要

The performances of four immunoassays (DRI amphetamines, DRI ecstasy, Abuscreen ONLINE amphetamines, and a modified Abuscreen ONLINE amphetamines) were evaluated for control failure rates, sensitivity, and specificity for amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA). The two DRI reagents and the ONLINE reagents were run according to manufacturer specifications using a Roche Hitachi Modular DDP system. The modified ONLINE reagent was calibrated with MDMA and had 16mM sodium periodate added to the R2 reagent. These assays were run on approximately 27,500 human urine samples and 7000 control urine samples prepared at 350 and 674 ng/mL over the course of 8 days. All assays were calibrated using a single point, qualitative cutoff standard with the manufacturer-recommended compound at the Department of Defense cutoff (500 ng/mL). Gas chromatography-mass spectrometry (GC-MS) confirmation was conducted on screened-positive samples. Control performance for the manufacturer recommended assays was excellent, with a maximum qualitative control failure rate of 2.03%. The modified ONLINE reagent demonstrated poor control performance with a maximum failure rate of 38.3% and showed no improved MDMA sensitivity when compared with the ONLINE reagent; the confirmation rate (20%) was improved when compared with the production ONLINE reagent (8%). The DRI ecstasy reagent provided improved sensitivity for MDMA as compared with the ONLINE reagent, with approximately 23% more samples screening and confirming positive for MDMA and a confirmation rate of approximately 90%. The DRI methamphetamine reagent had a low confirmation rate (6% or less) and produced numerous positives for samples with only ephedrine or pseudoephedrine present.
机译:评估了四种免疫测定(DRI苯丙胺,DRI摇头丸,Abuscreen ONLINE安非他明和改良的Abuscreen ONLINE安非他明)的控制失败率,灵敏度和对苯丙胺(AMP),甲基苯丙胺(MTH),3,4-亚甲基二氧苯丙胺的特异性(MDA)和3,4-亚甲二氧基甲基苯丙胺(MDMA)。两种DRI试剂和ONLINE试剂均使用Roche Hitachi Modular DDP系统根据制造商的说明运行。修饰的ONLINE试剂用MDMA校准,并向R2试剂中添加了16mM高碘酸钠。在8天的过程中,以350和674 ng / mL的浓度对大约27,500个人尿样品和7000对照尿样品进行了这些测定。所有测定均使用单点定性截止标准品和国防部截止值(500 ng / mL)上制造商推荐的化合物进行校准。气相色谱-质谱(GC-MS)确认是对筛选出的阳性样品进行的。制造商推荐的检测方法的对照性能优异,最大定性对照失败率为2.03%。与在线试剂相比,改性的在线试剂显示出较差的控制性能,最大失败率为38.3%,并且MDMA灵敏度没有提高。与生产的在线试剂(8%)相比,确认率(20%)提高了。与ONLINE试剂相比,DRI摇头丸试剂对MDMA的敏感性有所提高,样品筛选和确认MDMA阳性的样品多出约23%,确认率约为90%。 DRI甲基苯丙胺试剂的确证率低(6%或更低),并且对于仅含有麻黄碱或伪麻黄碱的样品产生了大量阳性结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号